{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:02:53Z","timestamp":1779814973839,"version":"3.53.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.radonc.2020.07.010","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T02:00:04Z","timestamp":1594778404000},"page":"245-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Brachytherapy in Belgium in 2018. A national survey of the brachytherapy study group of the Belgian SocieTy for Radiotherapy and Oncology (BeSTRO)"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9610-9136","authenticated-orcid":false,"given":"Carl","family":"Salembier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"De Hertogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8584-4189","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Daisne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Van Gestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.07.010_b0005","series-title":"Principles & practice of oncology","author":"DeVita","year":"2018"},{"key":"10.1016\/j.radonc.2020.07.010_b0010","series-title":"Radiotherapy and brachytherapy","author":"Lemoigne","year":"2009"},{"key":"10.1016\/j.radonc.2020.07.010_b0015","series-title":"Handbook of image-guided brachytherapy","author":"Mavadev","year":"2017"},{"key":"10.1016\/j.radonc.2020.07.010_b0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.addr.2016.09.002","article-title":"Advancements in brachytherapy","volume":"109","author":"Tanderup","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.radonc.2020.07.010_b0025","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1002\/cncr.28697","article-title":"The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base","volume":"120","author":"Martin","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2020.07.010_b0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.brachy.2013.08.005","article-title":"Declining use of brachytherapy for the treatment of prostate cancer","volume":"13","author":"Mahmood","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2020.07.010_b0035","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ijrobp.2014.07.017","article-title":"National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements","volume":"90","author":"Gill","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.010_b0040","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2014.59.8128","article-title":"Brachytherapy: where has it gone?","volume":"33","author":"Petereit","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0045","doi-asserted-by":"crossref","unstructured":"Van de Voorde C, Van den Heede K, Beguin C, Bouckaert N, Camberlin C, de Bekker P et al. Required hospital capacity in 2025 and criteria for rationalisation of complex cancer surgery, radiotherapy and maternity services. Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 2017 (289)","DOI":"10.57598\/R289C"},{"key":"10.1016\/j.radonc.2020.07.010_b0050","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5114\/jcb.2018.76981","article-title":"A national survey of AIRO (Italian Association of Radiation Oncology) brachytherapy (Interventional Radiotherapy) study group","volume":"10","author":"Autorino","year":"2018","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.radonc.2020.07.010_b0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1470-2045(12)70556-9","article-title":"Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database","volume":"14","author":"Rosenblatt","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.radonc.2020.07.010_b0060","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5114\/jcb.2016.61942","article-title":"Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated?","volume":"8","author":"Safdieh","year":"2016","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.radonc.2020.07.010_b0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2013.05.033","article-title":"Trends in the utilization of brachytherapy in cervical cancer in the United States","volume":"87","author":"Han","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.010_b0070","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2017.07.011","article-title":"Radiotherapy use in Belgium: How far are we from evidence-based utilization?","volume":"84","author":"Lievens","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2020.07.010_b0075","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2013.05.002","article-title":"GEC\/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update","volume":"107","author":"Hoskin","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0080","unstructured":"The Royal College of Radiologists: Quality Assurance Practice guidelines for transperineal LDR permanent seed brachytherapy of prostate cancer. The Royal College of Radiologist, London, 2012"},{"key":"10.1016\/j.radonc.2020.07.010_b0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2020.07.010_b0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2007.01.014","article-title":"Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO\/EAU\/EORTC recommendations onprostate brachytherapy","volume":"83","author":"Salembier","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0095","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2016.09.006","article-title":"American Brachytherapy Society Task Group Report: combination of brachytherapy and external beam radiation for high-risk prostate cancer","volume":"16","author":"Spratt","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2020.07.010_b0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clon.2015.02.005","article-title":"The Royal College of Radiologists\u2019 audit of prostate brachytherapy in the year 2012","volume":"27","author":"Stewart","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0110","series-title":"The role and development of brachytherapy services in the United Kingdom","author":"Royal College of Radiologists","year":"2007"},{"key":"10.1016\/j.radonc.2020.07.010_b0115","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ctrv.2013.10.006","article-title":"High dose rate brachytherapy boost for prostate cancer: a systematic review","volume":"40","author":"Zaorsky","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2020.07.010_b0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.010_b0125","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low- Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for Highand Intermediate-Risk Prostate Cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.010_b0130","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0135","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2217\/fon.15.14","article-title":"Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction","volume":"11","author":"Musunuru","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0140","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.clon.2013.04.009","article-title":"Brachytherapy: current status and future strategies \u2013 can high dose rate replace low dose rate and external beam radiotherapy?","volume":"25","author":"Morton","year":"2013","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0145","doi-asserted-by":"crossref","first-page":"238","DOI":"10.5114\/jcb.2018.76839","article-title":"UK & Ireland Prostate Brachytherapy Practice Survey 2014\u20132016","volume":"10","author":"Corey","year":"2018","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.radonc.2020.07.010_b0150","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.brachy.2011.01.003","article-title":"Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients","volume":"10","author":"Agoston","year":"2011","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2020.07.010_b0155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.brachy.2013.11.002","article-title":"The 15-year outcomes of high dose-rate brachytherapy for radical dose escalation in patients with prostate cancer e a benchmark for high-tech external beam radiotherapy alone?","volume":"13","author":"Galalae","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2020.07.010_b0160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.radonc.2015.02.023","article-title":"High doserate brachytherapy boost for intermediate risk prostate cancer: long-term outcomes of two different treatment schedules and early biochemical predictors of success","volume":"115","author":"Helou","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0165","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.radonc.2016.09.016","article-title":"A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients","volume":"121","author":"Joseph","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brachy.2012.05.003","article-title":"Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer","volume":"12","author":"Kotecha","year":"2013","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2020.07.010_b0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2019.08.017","article-title":"Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: analysis of over 500 patients","volume":"141","author":"Martell","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0180","first-page":"43","article-title":"High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short and medium-term urinary toxicity and biochemical control","volume":"4","author":"Pellizzon","year":"2011","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.radonc.2020.07.010_b0185","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/j.1464-410X.2011.10632.x","article-title":"Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience","volume":"109","author":"Prada","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2020.07.010_b0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2012.11480.x","article-title":"High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high- risk prostate cancer: 10-year biochemical freedom from relapse","volume":"110","author":"Savdie","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2020.07.010_b0195","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9\u201310 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2020.07.010_b0200","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijrobp.2018.07.316","article-title":"A phase II randomized pilot study comparing high-dose rate brachytherapy and low-dose rate brachytherapy as monotherapy in localized prostate cancer","volume":"102","author":"Hathout","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.010_b0205","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijrobp.2013.01.027","article-title":"Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-years outcomes","volume":"86","author":"Chen","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.010_b0210","doi-asserted-by":"crossref","first-page":"S588","DOI":"10.1016\/S0167-8140(19)31476-8","article-title":"Ultra-focal salvage HDR-brachytherapy for recurrent prostate cancer: a single institution experience","volume":"133","author":"Salembier","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0215","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.radonc.2019.09.006","article-title":"Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: a comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy","volume":"141","author":"Lopez","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0220","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high intermediate risk (PORTEC-2): an open-label, noninferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2020.07.010_b0225","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2020.07.010_b0230","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.radonc.2020.07.010_b0235","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ygyno.2014.12.036","article-title":"The role of vaginal cuff brachytherapy in endometrial cancer","volume":"136","author":"Harkenrider","year":"2015","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.radonc.2020.07.010_b0240","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.ijrobp.2008.03.032","article-title":"Image-guided radiotherapy for cervix cancer: High-tech external beam therapy versus high-tech brachytherapy","volume":"71","author":"Georg","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.010_b0245","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.radonc.2011.07.012","article-title":"Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer","volume":"100","author":"P\u00f6tter","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0250","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3109\/0284186X.2013.818253","article-title":"MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective","volume":"52","author":"Lindegaard","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0255","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ijrobp.2014.07.017","article-title":"National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements","volume":"90","author":"Gill","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.010_b0260","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2013.11.011","article-title":"Curative radiation therapy for locally advanced cervical cancer: brachytherapy is NOT optional","volume":"88","author":"Tanderup","year":"2014","journal-title":"Int J Radiation Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.010_b0265","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.radonc.2017.07.015","article-title":"Partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy. Long-term results of a phase II prospective study","volume":"124","author":"Aristei","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijrobp.2010.01.020","article-title":"Accelerated partial breast irradiation: 5-year results of the German-Austrian multi- center phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery","volume":"80","author":"Strnad","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.010_b0275","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.radonc.2015.03.002","article-title":"Clinical outcomes of prospectively treated 140 women with early stage breast cancer using accelerated partial breast irradiation with 3-dimensional computerized tomography-based brachytherapy","volume":"115","author":"Budrukkar","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0280","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(15)00471-7","volume":"387","author":"Strnad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2020.07.010_b0285","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: twelve-year mortality rates and prognostic factors: COMS report No 28","volume":"124","author":"Collaborative Ocular Melanoma Study Group","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.radonc.2020.07.010_b0290","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.radonc.2018.03.019","article-title":"Dose-response in choroidal melanoma","volume":"127","author":"De Caluw\u00e9","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0295","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.clon.2019.08.004","article-title":"Current role of radiotherapy in non-melanoma skin cancer","volume":"31","author":"Veness","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0300","first-page":"1","article-title":"Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American Society for Radiation Oncology clinical practice guideline","volume":"1","author":"Likhacheva","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2059513119891113","article-title":"Surgical excision and postoperative radiotherapy for keloids","volume":"5","author":"Ogawa","year":"2019","journal-title":"Scars Burns Healing"},{"key":"10.1016\/j.radonc.2020.07.010_b0310","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.radonc.2016.12.022","article-title":"GEC-ESTRO\/ACROP recommendations for performing bladdersparing treatment with brachytherapy for muscle-invasive bladder cancer","volume":"122","author":"Pieters","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0315","doi-asserted-by":"crossref","DOI":"10.2217\/crc-2019-0006","article-title":"The role of external beam and endoluminal radiation boosting in rectal cancer","volume":"8","author":"Berb\u00e9e","year":"2019","journal-title":"Colorect Cancer"},{"key":"10.1016\/j.radonc.2020.07.010_b0320","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.radonc.2006.11.011","article-title":"Overview of brachytherapy resources in Europe: a survey of patterns of care study for brachytherapy in Europe","volume":"82","author":"Guedea","year":"2007","journal-title":"Radioth Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0325","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.radonc.2010.09.009","article-title":"Patterns of care for brachytherapy in Europe: Updated results","author":"Guedea","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.010_b0330","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5114\/jcb.2010.19493","article-title":"Patterns ofcare study for brachytherapy: results of the questionnaire for the years 2002 and 2007 in The Netherlands","volume":"2","author":"Venselaar","year":"2010","journal-title":"J Contemp Brachyther"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020304035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020304035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:09:06Z","timestamp":1779811746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020304035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":66,"alternative-id":["S0167814020304035"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.07.010","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brachytherapy in Belgium in 2018. A national survey of the brachytherapy study group of the Belgian SocieTy for Radiotherapy and Oncology (BeSTRO)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}